Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

AALL1731: This Phase III trial is evaluating how well targeted therapy (blinatumomab) works in combination with chemotherapy in treating people with newly diagnosed, standard risk B-lymphoblastic leukaemia or B-lymphoblastic lymphoma.A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This is a randomised, open-label trial with multiple active comparator and experimental arms investigating Blinatumomab in combination with chemotherapy in patients with newly diagnosed standard risk or Down Syndrome B-Lymphoblastic Leukaemia (B-ALL) and the treatment of patients with localised B-Lymphoblastic Lymphoma (B-LLy). The trial is seeking to determine whether the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival.

Age

People 1 - 31

Phase

III

Trial Acronym

AALL1731

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT03914625

Commercial Sponsor

National Cancer Institute (NCI)

Scientific Title

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Share with email